Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy.
Mingjia LiSongzhu ZhaoGabrielle LopezAustin SecorParthib DasNitya SuryaMadison GroganSandip PatelKarthik ChakravarthyAbdul MiahDaniel SpakowiczGabriel TinocoZihai LiLai WeiKai HeErin BertinoAsrar AlahmadiRegan MemmottJacob KaufmanPeter G ShieldsDavid P CarboneCarolyn J PresleyGregory A OttersonDwight H OwenPublished in: Cancer immunology, immunotherapy : CII (2023)
Change in MPV after 1 cycle of pembrolizumab-based treatment was significantly associated with overall survival as well as the occurrence of irAEs in patients with metastatic NSCLC in the first-line setting. In addition, thrombocytosis was associated with poor survival.